Stockscreener 앱 받기
186.42
4.68%
8.34
전일 마감가:
$178.08
열려 있는:
$178.08
하루 거래량:
868.03K
Relative Volume:
1.10
시가총액:
$3.92B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-20.33
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+10.82%
1개월 성능:
+254.95%
6개월 성능:
+402.48%
1년 성능:
+142.48%
1일 변동 폭
$175.79
$197.55
1주일 범위
$160.38
$197.55
52주 변동 폭
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
186.42 | 4.45B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
How analysts rate Praxis Precision Medicines Inc. stock todayPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
How institutional buying supports Praxis Precision Medicines Inc. stockJuly 2025 Momentum & Free Fast Entry Momentum Trade Alerts - newser.com
Using fundamentals and technicals on Praxis Precision Medicines Inc.2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Is Praxis Precision Medicines Inc. stock a contrarian buy2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesMarket Growth Summary & Weekly Setup with High ROI Potential - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockWeekly Risk Summary & Smart Allocation Stock Reports - newser.com
PRAX: HC Wainwright & Co. Raises Price Target to $258 | PRAX Sto - GuruFocus
Published on: 2025-11-12 17:26:58 - newser.com
Published on: 2025-11-12 08:52:54 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsWeekly Earnings Recap & Community Verified Trade Signals - newser.com
(PRAX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Published on: 2025-11-10 01:11:09 - newser.com
Published on: 2025-11-09 22:42:30 - newser.com
Praxis Precision Medicines Reports Q3 2025 Financial Results - MSN
Published on: 2025-11-08 04:02:56 - newser.com
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $270 From $280, Maintains Buy Rating - MarketScreener
Praxis Precision Medicines (PRAX) Is Up After Positive Ulixacaltamide Trial and FDA Alignment on RelutrigineHas the Investment Thesis Gained New Momentum? - Sahm
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline - Investing.com Canada
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline By Investing.com - Investing.com South Africa
Wedbush Raises Price Target on Praxis Precision Medicines to $77 From $73, Keeps Underperform Rating - MarketScreener
PRAX: Wedbush Raises Price Target While Maintaining Underperform Rating | PRAX Stock News - GuruFocus
Praxis Precision announces inducement grants under Nasdaq lsiting rule - TipRanks
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) grants 6,876 RSUs under 2024 Inducement Plan - Stock Titan
Is a relief rally coming for Praxis Precision Medicines Inc. holders2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - Markets Financial Content
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beat2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.07%
자본화:
|
볼륨(24시간):